It wasn’t supposed to go this way. Daiichi Sankyo bet big, big money that it’s safer, more effective version of Lyrica (pregabalin) called mirogabalin was going to be the next big thing in fibromaylgia (FM). It was so confident that it embarked on a...
The current crop of FM drugs is hardly the cat’s meow but a recent study suggests that with FM drugs more might be better; i.e. combining drugs – perhaps in lower doses – might help both drugs to work better. Find out more in Combining Drugs May Work...
Tomnya had everything going for it; a novel approach to pain and good Phase II trial results, but Tonix’s reformulation of Flexeril that was expected to help with both sleep and pain tanked in its critical Phase III trial. Check out what happened with it, and...
Pharmaceutical Processing predicts the market for fibromyalgia drugs will grow to 1.9 billion dollars a year by the 2023. The basis for their predictions are the introduction of generics for currently approved FDA drugs for FM and the introduction of four...
The Pain Brain Sometimes you’ve got to ask wonder where is it going to stop with fibromyalgia (FM) and the brain? Reductions in the volume of “gray matter” (the neuronal cell bodies and glial cells as opposed to the long nerve fibers) have been found...
Keep the information flowing! Support Health Rising during our end of the year fundraising drive. Click here for more.
Stay Up to Date with ME/CFS, Long COVID and Fibromyalgia News
Get Health Rising's free blogs featuring the latest findings and treatment options for the ME/CFS, long COVID, fibromyalgia and complex chronic disease communities.